|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cerebral Hemorrhage | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Hemorrhage | |||||
| 3 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Cardiovascular Diseases | |||||
| Central Nervous System Diseases | |||||
| Cerebrovascular Disorders | |||||
| Intracranial Hemorrhages | |||||
| Nervous System Diseases | |||||
| Pathologic Processes | |||||
| Vascular Diseases | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Plasminogen | |||||
| Tissue Plasminogen Activator | |||||
| 5 | More general drug interventions related to this trial | ||||
| Cardiovascular Agents | |||||
| Fibrin Modulating Agents | |||||
| Fibrinolytic Agents | |||||
| Hematologic Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| FDA Office of Orphan Products Development | |||||